Flerie AB’s (publ) portfolio company Lipum AB has been selected for an EUR 8 million grant from the European Union’s Horizon Europe Research and Innovation Programme. Lipum will lead a consortium under the call “Boosting the translation of biotech research into innovative health therapies”.

The funding, pending final negotiations, will support a Phase 2 clinical proof-of-concept study of Lipum’s drug candidate, SOL-116, being developed as a potential treatment for moderate to severe rheumatoid arthritis. Lipum leads the consortium along with three European partners, each providing expertise to help transition promising biotech research into clinical applications.

”The fact that the consortium led by Lipum has secured this EUR 8 million grant is a testament to the scientific excellence and the capacity to deliver significant innovations to patients. This non-dilutive funding boosts Lipum’s financial stability and speeds up clinical development, generating benefits for both patients and shareholders,” says Ted Fjällman, CEO of Flerie.

SOL-116 is a humanised monoclonal antibody targeting Bile Salt-Stimulated Lipase (BSSL), a novel therapeutic target identified by Lipum. This offers a new mechanism of action for treating chronic inflammation and could significantly improve outcomes for the estimated 18 million people worldwide living with rheumatoid arthritis.

Flerie has long been the largest shareholder in Lipum and, pending the completion of the published merger process, Lipum will become a wholly-owned private subsidiary to Flerie by the end of March 2026.

Read Lipum’s full press release here:
https://lipum.se/blog/mfn_news/lipum-selected-for-horizon-europe-grant/

For more information:
Ted Fjällman, CEO
Email: ir@flerie.com

About Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disorder where the immune system attacks joint linings, causing painful swelling, stiffness, and symmetrical joint damage. Primarily affecting the hands and wrists, it can cause deformity and affect organs such as the lungs or heart. Early diagnosis and medication (DMARDs) are crucial to prevent permanent damage. The current medication primarily reduces symptoms but does not address the underlying cause.

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments
Flerie’s portfolio company Lipum selected for EUR 8 million Horizon Europe grant

Läs mer på MFN